Corvus Pharmaceuticals Inc
NASDAQ:CRVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Corvus Pharmaceuticals Inc
NASDAQ:CRVS
|
US |
|
A
|
Alzchem Group AG
DUS:ACT
|
DE |
|
Etteplan Oyj
F:EPL
|
FI |
|
R
|
RPCG PCL
SET:RPC
|
TH |
|
Bank Mega Tbk PT
IDX:MEGA
|
ID |
Intrinsic Value
Is CRVS undervalued or overvalued?
See the intrinsic value estimate for Corvus Pharmaceuticals Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
CRVS looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with CRVS’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Corvus Pharmaceuticals Does
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company that tries to turn lab discoveries into new medicines for immune-related diseases and cancer. It does not sell a broad line of approved drugs. Instead, it advances a small group of drug candidates through preclinical work and clinical trials to see whether they are safe and effective enough for approval.
- Headquarters
- United States of America US
- Employees
- 29
- IPO date
- Mar 23, 2016
Revenue & Expenses Breakdown
Corvus Pharmaceuticals Inc
Earnings Waterfall
Corvus Pharmaceuticals Inc
The intrinsic value for Corvus Pharmaceuticals Inc (CRVS) under the Base Case is hidden USD.
Compared with the current market price of 9.85 USD, the stock appears hidden.